论文部分内容阅读
江西突破式的药价改革日前浮出水面,在全国范围内率先放开省管的601种非处方药品价格。江西省于10月22日正式发布《关于进一步深化价格管理改革的意见》,同步放开省管的601种非处方药品价格。放开后,原省管价格的非处方药品,省价格主管部门不再制定最高零售价,药品生产经营企业参与市场竞争,在市场规则下优胜劣汰,根据市场供求关系,由企业自主制定价格。此举被认为是近年来中国药价改革的一个标志性举措,撕开了政府强制制定药价的口子,是政府减政放权、“主权”回
Jiangxi breakthrough drug prices surfaced a few days ago, the first in the country to liberalize the 601 kinds of non-prescription drug prices. Jiangxi Province formally released Opinions on Further Deepening Price Management Reform on October 22 and simultaneously released 601 kinds of non-prescription drug prices under provincial control. After letting go, the over-the-counter pharmaceutical and provincial pricing authorities at the provincial level no longer set a maximum retail price. Pharmaceutical production and operation enterprises are involved in market competition and the survival of the fittest under the market rules. According to the market supply and demand, the enterprises themselves formulate the prices. The move is considered to be an landmark measure of drug price reform in China in recent years, ripped open the mouth of the government forcing drug prices to be drafted by the government,